Science Corporation, a brain-computer interface (BCI) developer founded by Neuralink co-founder Max Hodak, has acquired the IP and related assets for Pixium Vision’s Prima implant. This acquisition includes the retinal implant technology developed by Pixium Vision, which has already received FDA breakthrough device designation. The Prima System, a photovoltaic substitute of photoreceptors, is designed for patients with atrophic dry age-related macular degeneration (AMD) and allows for simultaneous use of central prosthetic and peripheral natural vision.
Pixium Vision, based in France, had been looking for a potential buyer and saw Science Corporation as a promising partner to further develop BCI technology for vision restoration through the acquisition of the Prima implant. Science Eye, another product developed by Science Corporation, is a visual prosthesis targeting retinitis pigmentosa (RP) and dry AMD. The company believes that the addition of the Prima implant technology will expand their IP portfolio and provide continuity and a future for patients enrolled in Pixium clinical trials.
CEO Max Hodak expressed excitement about the acquisition, stating that Science Corporation is now developing innovative products using two different modalities. With the addition of the Prima implant technology, Science Corporation aims to continue its mission of helping patients with vision impairments. Outgoing Pixium CEO Lloyd Diamond expressed confidence in the acquisition, believing that Prima now has a home with a team dedicated to helping patients. The terms of the deal were not disclosed, but both companies are committed to working together to advance BCI technology for the benefit of patients.
Science Corporation’s acquisition of Pixium Vision’s IP and related assets marks an important step forward in the development of brain-computer interfaces for vision restoration. With their growing portfolio of products and expertise in this field, Science Corporation is well positioned to continue making strides towards improving outcomes for patients with vision impairments.
